|
11.
|
|
2.1 MB |
Efectividad y seguridad de los nuevos tratamientos para la psoriasis moderada- grave en la práctica clínica real
/
del Alcázar Viladomiu, Elena ;
Carrascosa, José Manuel, dir.
Les dades d'efectivitat i seguretat d'un fàrmac a la vida real es consideren essencials per a ponderar els resultats dels assaigs pivotals per a la presa de decisions dels clínics. L'objectiu va ser el de avaluar l'efectivitat i seguretat de nous fàrmacs per al tractament de la psoriasi moderada-greu. [...]
Los datos de efectividad y seguridad de un fármaco en vida real se consideran esenciales para ponderar los resultados de los ensayos pivotales para la toma de decisiones de los clínicos. El objetivo fue evaluar la efectividad y seguridad de nuevos fármacos para el tratamiento de la psoriasis moderada-grave. [...]
Physicians must evaluate the results of pivotal trials together with real-world data on effectiveness and safety when making clinical decisions. The objective was to evaluate the safety and effectiveness of new drugs for the treatment of moderate to severe psoriasis in clinical practice. [...]
2022
|
|
|
12.
|
|
9 p, 823.5 KB |
The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
/
Maravilla-Herrera, Paulina (Weber) ;
Merino, María (Weber) ;
Alfonso Zamora, Santiago (Acción Psoriasis) ;
Balea Filgueiras, Jesús (Complejo Hospitalario Universitario de Ferrol) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Delgado Sánchez, Olga (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Dolz Sinisterra, Francisco (Hospital Universitari Doctor Peset (València)) ;
García-Ruiz, Antonio (Universidad de Málaga) ;
Herranz Pinto, Pedro (Hospital Universitario La Paz (Madrid)) ;
Manfredi, Antonio (Acción Psoriasis) ;
Martínez Olmos, José (Escuela Andaluza de Salud Pública (EASP)) ;
Morales de los Ríos Luna, Paloma (Hospital General Universitario Gregorio Marañón) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Ros Abarca, Sandra (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Hidalgo, Álvaro (Fundación Weber) ;
Universitat Autònoma de Barcelona
Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i. e. , response) are assessed through the Psoriasis Area and Severity Index (PASI). [...]
2023 -  10.3389/fpubh.2023.1000776
Frontiers in Public Health, Vol. 11 (january 2023)
|
|
|
13.
|
|
13 p, 1.2 MB |
The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease
/
Olveira, Antonio (Hospital Universitario La Paz (Madrid)) ;
Augustin Recio, Salvador (Hospital Universitari Vall d'Hebron) ;
Benlloch, Salvador (Hospital Arnau de Vilanova (València)) ;
Ampuero, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Suárez-Pérez, Jorge Alonso (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Armesto, Susana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Vilarrasa-Rull, Eva (Institut d'Investigació Biomèdica Sant Pau) ;
Belinchón, Isabel (Universidad Miguel Hernández de Elche) ;
Herranz, Pedro (Hospital Universitario La Paz (Madrid)) ;
Crespo García, Javier (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Guimerá, Francisco (Hospital Universitario de Canarias (La Laguna)) ;
Gómez-Labrador, Lara (Novartis Farmacéutica (Madrid)) ;
Martín, Víctor (Novartis Farmacéutica (Madrid)) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Interleukin 17 (IL-17) is an effector cytokine that plays a key role in the pathogenesis of both psoriasis and metabolic-associated fatty liver disease (MAFLD), a condition that is more prevalent and severe in patients with psoriasis. [...]
2023 - 10.3390/life13020419
Life, Vol. 13 (february 2023)
|
|
|
14.
|
|
20 p, 724.5 KB |
From messengers to receptors in psoriasis : The role of il-17ra in disease and treatment
/
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
González-Cantero, Á. (Psoriasis and Inflammatory Skin Diseases Unit. Grupo Pedro Jaen) ;
Ruiz-Carrascosa, J.C. (Hospital Universitario San Cecilio (Granada)) ;
Velasco-Pastor, A.M. (Hospital Arnau de Vilanova (València))
The paradigm of psoriasis as a Th17-driven disease has evolved in the last years towards a much deeper knowledge of the complex pathways, mechanisms, cells, and messengers involved, highlighting the crucial role played by the IL-17 family of cytokines. [...]
2021 - 10.3390/ijms22136740
International journal of molecular sciences, Vol. 22 Núm. 13 (january 2021) , p. 6740
|
|
|
15.
|
|
|
16.
|
|
3 p, 147.0 KB |
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab
/
Brunner, Patrik M. (Medical University of Vienna) ;
Conrad, Curdin (Lausanne University Hospital) ;
Vender, Ronald (Dermatrials Research Inc) ;
Grond, Susanne (Eli Lilly and Company, Indianapolis) ;
Schuster, Christopher F. (Eli Lilly and Company, Indianapolis) ;
Patel, Hanna (Eli Lilly and Company, Indianapolis) ;
Xu, Wen (Eli Lilly and Company, Indianapolis) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
2021 - 10.1111/bjd.20527
British journal of dermatology, Vol. 185 (august 2021) , p. 865-867
|
|
|
17.
|
|
10 p, 2.1 MB |
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks : A retrospective, observational, multicentre study by the Spanish Psoriasis Group
/
del Alcázar Viladomiu, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
López-Ferrer, Anna (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez-Doménech, Álvaro (Hospital General Universitario de Valencia) ;
Ruíz Villaverde, Ricardo (Hospital Universitario San Cecilio (Granada)) ;
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid)) ;
Rocamora, V. (Hospital de Manacor) ;
Julià, M. (Hospital de Basurto (Bilbao, Biscaia)) ;
Notario, J. (Hospital Universitari de Bellvitge) ;
Fernández-Freire, L. R. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sahuquillo-Torralba, A. (Hospital Universitari i Politècnic La Fe (València)) ;
Vidal, D. (Hospital de Sant Joan Despí Moisès Broggi) ;
Rivera, Raquel (Hospital Universitario 12 de Octubre (Madrid)) ;
Carretero, G. (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Mateu, A. (Hospital Universitari Doctor Peset (València)) ;
De la Cueva, Pablo (Hospital Universitario Infanta Leonor) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Data on the effectiveness and safety of a drug in real-world clinical practice complement the evidence from clinical trials, which are carried out in a different setting. Little has been published on the effectiveness and safety of guselkumab in the treatment of psoriasis in clinical practice. [...]
2021 - 10.1111/dth.15231
Dermatologic therapy, 2021
|
|
|
18.
|
|
16 p, 2.0 MB |
Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors
/
Kokolakis, Georgios (Charité-Universitätsmedizin Berlin. Clinic of Dermatology, Venereology and Allergology, Psoriasis Research and Treatment Centre) ;
Vadstrup, Kasper (LEO Pharma A/S) ;
Hansen, Jes Birger (LEO Pharma A/S) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Obesity, smoking, and alcohol consumption are prevalent in psoriasis patients and have been associated with increased disease severity and reduced treatment adherence and response. This post hoc analysis of pooled data from the phase 3 AMAGINE-2 and -3 trials compared the efficacy of brodalumab versus ustekinumab in psoriasis patients with aggravating and potentially treatment-confounding lifestyle risk factors. [...]
2021 - 10.1007/s13555-021-00618-5
Dermatology and Therapy, Vol. 11 (october 2021) , p. 2027-2042
|
|
|
19.
|
|
11 p, 532.2 KB |
The Role of Photoprotection in Optimizing the Treatment of Atopic Dermatitis
/
Piquero-Casals, Jaime (Dermik. Multidisciplinary Dermatology Clinic) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morgado-Carrasco, Daniel (Hospital Clínic i Provincial de Barcelona) ;
Narda, Mridvika (ISDIN. Innovation and Development) ;
Trullas, Carles (ISDIN. Innovation and Development) ;
Granger, Corinne (ISDIN. Innovation and Development) ;
Fabbrocini, Gabriella (University of Naples Federico II. Department of Clinical Medicine and Surgery) ;
Universitat Autònoma de Barcelona
Atopic dermatitis (AD) is a chronic inflammatory skin disease with an estimated prevalence of 10-15% in children and 2-10% in adults. Clinically, there is notable phenotypic variability driven by a complex interaction between genetics, immune function, and the environment. [...]
2021 - 10.1007/s13555-021-00495-y
Dermatology and Therapy, Vol. 11 (february 2021) , p. 315-325
|
|
|
20.
|
|
22 p, 792.5 KB |
Biosimilar Drugs for Psoriasis : Principles, Present, and Near Future
/
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Jacobs, Ira (Pfizer Inc) ;
Petersel, Danielle (Pfizer Inc) ;
Strohal, Robert (Federal Academic Teaching Hospital of Feldkirch) ;
Universitat Autònoma de Barcelona
Psoriasis is a chronic, inflammatory, lifelong disease with a high prevalence (afflicting approximately 1-5% of the population worldwide) and is associated with significant morbidity. The introduction of biologic therapies has improved the management of this disease. [...]
2018 - 10.1007/s13555-018-0230-9
Dermatology and Therapy, Vol. 8 (march 2018) , p. 173-194
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
